Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 30.70
+0.10 (0.33%)
At close: Jan 22, 2026
Prince Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| 798.27 | 690.03 | 753.33 | 712.53 | 441.08 | 295.79 | Upgrade | |
Revenue Growth (YoY) | 8.29% | -8.40% | 5.73% | 61.54% | 49.12% | 18.50% | Upgrade |
Cost of Revenue | 681.34 | 615.75 | 600.23 | 506.74 | 315.59 | 206.82 | Upgrade |
Gross Profit | 116.94 | 74.28 | 153.09 | 205.79 | 125.49 | 88.98 | Upgrade |
Selling, General & Admin | 73.48 | 75.43 | 72.74 | 65.9 | 47.38 | 61.15 | Upgrade |
Research & Development | 41.11 | 48.2 | 54.67 | 72.05 | 79.21 | 78.22 | Upgrade |
Operating Expenses | 114.6 | 123.63 | 127.31 | 138.03 | 126.6 | 139.26 | Upgrade |
Operating Income | 2.34 | -49.35 | 25.78 | 67.76 | -1.11 | -50.28 | Upgrade |
Interest Expense | -9.99 | -10.27 | -10.46 | -8.94 | -7.55 | -5.31 | Upgrade |
Interest & Investment Income | 0.97 | 1.3 | 1.16 | 0.22 | 0.03 | 0.17 | Upgrade |
Currency Exchange Gain (Loss) | -3.03 | - | - | 4.18 | -1 | -0.8 | Upgrade |
Other Non Operating Income (Expenses) | 4.61 | 6.38 | 2.63 | 0.92 | -0.76 | 15.02 | Upgrade |
EBT Excluding Unusual Items | -5.11 | -51.95 | 19.11 | 64.14 | -10.4 | -41.2 | Upgrade |
Gain (Loss) on Sale of Assets | 0.07 | -0.14 | 0.06 | 0.06 | 0.09 | -0.25 | Upgrade |
Pretax Income | -5.04 | -52.08 | 19.17 | 64.2 | -10.31 | -41.44 | Upgrade |
Income Tax Expense | 5.9 | 1.46 | 3.86 | 12.65 | -2.01 | -7.64 | Upgrade |
Net Income | -10.94 | -53.54 | 15.31 | 51.55 | -8.3 | -33.8 | Upgrade |
Net Income to Common | -10.94 | -53.54 | 15.31 | 51.55 | -8.3 | -33.8 | Upgrade |
Net Income Growth | - | - | -70.30% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 37 | 37 | 36 | 33 | 33 | 33 | Upgrade |
Shares Outstanding (Diluted) | 37 | 37 | 37 | 33 | 33 | 33 | Upgrade |
Shares Change (YoY) | 0.34% | 0.09% | 9.66% | 0.41% | 1.45% | 2.07% | Upgrade |
EPS (Basic) | -0.30 | -1.46 | 0.43 | 1.55 | -0.25 | -1.03 | Upgrade |
EPS (Diluted) | -0.30 | -1.46 | 0.42 | 1.55 | -0.25 | -1.03 | Upgrade |
EPS Growth | - | - | -72.90% | - | - | - | Upgrade |
Free Cash Flow | 30.45 | 28.21 | 0.45 | 72.13 | 1.38 | -186.73 | Upgrade |
Free Cash Flow Per Share | 0.83 | 0.77 | 0.01 | 2.16 | 0.04 | -5.71 | Upgrade |
Dividend Per Share | - | - | 0.250 | 0.150 | - | - | Upgrade |
Dividend Growth | - | - | 66.67% | - | - | - | Upgrade |
Gross Margin | 14.65% | 10.76% | 20.32% | 28.88% | 28.45% | 30.08% | Upgrade |
Operating Margin | 0.29% | -7.15% | 3.42% | 9.51% | -0.25% | -17.00% | Upgrade |
Profit Margin | -1.37% | -7.76% | 2.03% | 7.23% | -1.88% | -11.43% | Upgrade |
Free Cash Flow Margin | 3.82% | 4.09% | 0.06% | 10.12% | 0.31% | -63.13% | Upgrade |
EBITDA | 56.35 | 4.54 | 75.94 | 113.7 | 40.05 | -26.52 | Upgrade |
EBITDA Margin | 7.06% | 0.66% | 10.08% | 15.96% | 9.08% | -8.96% | Upgrade |
D&A For EBITDA | 54.01 | 53.89 | 50.16 | 45.93 | 41.16 | 23.76 | Upgrade |
EBIT | 2.34 | -49.35 | 25.78 | 67.76 | -1.11 | -50.28 | Upgrade |
EBIT Margin | 0.29% | -7.15% | 3.42% | 9.51% | -0.25% | -17.00% | Upgrade |
Effective Tax Rate | - | - | 20.12% | 19.70% | - | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.